Bluejay Diagnostics(NASDAQ) BJDX

Bluejay Diagnostics makes blood tests for hospitals and clinics.

Gadgets and Gizmos: Bluejay’s Main Offerings

Symphony Platform: Mobile blood testing device for hospitals; no revenue as of September 2024.

Symphony Cartridge Library: Single-use test cartridges for the Symphony device; no revenue reported.

ALLEREYE Diagnostic Test: Point-of-care test for allergic eye conditions; no sales yet.

Cardiac Biomarker Tests: In development for heart injury and failure; not yet commercialized.

Biomarker Development: Research on new disease markers for future tests; pre-commercial stage.

Growth Spurts and Strategic Moves

Signed a license and supply agreement with Toray Industries in October 2023 for protein chip technology.

Completed SYMON-I clinical study for Symphony IL-6 test in 2024.

Started SYMON-II pivotal clinical study in Q3 2024 for sepsis risk testing.

Developing plans, as of 2024, to transfer cartridge production and supply chain activities to an FDA-registered contract manufacturer.

Reverse stock split (1-for-8) effective June 2024 to meet NASDAQ rules.

What Makes Bluejay Stand Out (Besides the Name)

Bluejay focuses on rapid, on-site blood testing for critical care settings. Its technology uses single-use cartridges and aims for results in under 20 minutes. The company partners with global firms for technology and manufacturing but remains pre-commercial.

Five Things You Need to Know

No product revenue reported .

Reported a net loss of $6.3 million .

Cash and cash equivalents (GAAP) totaled $5.8 million at the end of Q3 2024.

Operating expenses were $5.7 million .

Company expects cash to last only through Q1 2025 without new funding.

Bottom Line

Bluejay remains in the development stage, with no commercial sales and ongoing technical challenges. Its future depends on successful product launches and securing additional funding.